

1617148601?pwd=eVBTM0dweHFx  
QUxWUzU2OEtY1R1QT09, webinar ID:  
161 714 8601, and passcode: v08w0@e5.

**FOR FURTHER INFORMATION CONTACT:**

Staci Morris, Committee Management Specialist, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8–6, Atlanta, Georgia 30329–4027, Telephone: (404) 718–7479; [smorris4@cdc.gov](mailto:smorris4@cdc.gov).

**SUPPLEMENTARY INFORMATION:** Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below by Monday, April 19, 2021. Persons who desire to make an oral statement, may request it at the time of the public comment period on April 20, 2021 at 4:25 p.m., EDT.

**Purpose:** This committee is charged with advising the Director, CDC, and the Administrator, HRSA, regarding activities related to prevention and control of HIV, Viral Hepatitis and other STDs, the support of health care services to persons living with HIV, and education of health professionals and the public about HIV, Viral Hepatitis and other STDs.

**Matters To Be Considered:** The agenda will include discussions on (1) STI Screening and Diagnostics; (2) Innovation and COVID–19; and (3) Youth and Mental Health. Agenda items are subject to change as priorities dictate.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2021–03962 Filed 2–25–21; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT)**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the CDC and the Health Resources and Services Administration (HRSA) announce the following meeting for the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT). This business meeting is open to the public, limited only by audio and web conference lines (1000 audio and web conference lines are available). The public is welcome to listen to the meeting by accessing the telephone number 1–669–254–5252, and the passcode is 55572151 (1000 lines are available). The web conference access is <https://cdc.zoomgov.com/j/1606419940?pwd=V2krVkVXbGtvVFdLbXV3N25PbTV4UT09>, webinar ID: 160 641 9940 and passcode: ZeTt@2VL.

**DATES:** The business meeting will be held on April 12, 2021, from 3:00 p.m. to 5:00 p.m., EDT.

**ADDRESSES:** The teleconference access is 1–669–254–5252, and the passcode is 55572151. The web conference access is <https://cdc.zoomgov.com/j/1606419940?pwd=V2krVkVXbGtvVFdLbXV3N25PbTV4UT09>, webinar ID: 160 641 9940 and passcode: ZeTt@2VL.

**FOR FURTHER INFORMATION CONTACT:**

Staci Morris, Committee Management Specialist, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8–6, Atlanta, Georgia 30329–4027, Telephone (404) 718–7479; [smorris4@cdc.gov](mailto:smorris4@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

**Purpose:** This committee is charged with advising the Director, CDC and the Administrator, HRSA, regarding activities related to prevention and control of HIV, Viral Hepatitis and other STDs, the support of health care services to persons living with HIV/AIDS, and education of health professionals and the public about HIV, Viral Hepatitis and other STDs.

**Matters To Be Considered:** The agenda will include discussions on (1) HIV Testing Guidelines; and (2) FDA

reclassification, home-based HIV self-tests and point-of-care testing for HCV. Agenda items are subject to change as priorities dictate.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2021–03961 Filed 2–25–21; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Clinical Laboratory Improvement Advisory Committee (CLIAC)**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Clinical Laboratory Improvement Advisory Committee (CLIAC). This meeting is open to the public, limited only by the webcast lines available. Check the CLIAC website on the day of the meeting for the web conference link [www.cdc.gov/cliac](http://www.cdc.gov/cliac).

**DATES:** The meeting will be held on April 14, 2021, from 11:00 a.m. to 6:00 p.m., EDT and April 15, 2021, from 11:00 a.m. to 6:00 p.m., EDT.

**ADDRESSES:** This is a virtual meeting. Meeting times are tentative and subject to change. The confirmed meeting times, agenda items, and meeting materials including instructions for accessing the live meeting broadcast will be available on the CLIAC website at [www.cdc.gov/cliac](http://www.cdc.gov/cliac).

**FOR FURTHER INFORMATION CONTACT:**

Nancy Anderson, MMSc, MT (ASCP), Senior Advisor for Clinical Laboratories, Division of Laboratory Systems, Center for Surveillance, Epidemiology and Laboratory Services, Office of Public Health Scientific Services, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop V24–3,